Suggested remit - To appraise the clinical and cost effectiveness of depatuxizumab mafodotin within its marketing authorisation for treating newly diagnosed EGFR-amplified glioblastoma multiforme
Following on from information provided to NICE by the company in June 2019, the appraisal of Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1466
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2019, the appraisal of Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 04 June 2019 | Note added to the project documents |
| 21 March 2017 | Referral |
| 21 March 2017 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual